batroxobin
Commercial- Indications
- Acute cerebral infarction, Angina pectoris, Sudden deafness, Hemostasis
Company intelligence / Profile preview
Pentapharm AG has a long-standing tradition as an innovative supplier of active pharmaceutical ingredients (APIs) and diagnostic reagents for coagulation. Their products are used globally in both clinical diagnostics and as APIs for pharmaceuticals targeting hemostasis and thrombosis. The company holds Drug Master Files (DMFs) and Certificates of Suitability for key products such as Aprotinin, Batroxobin (Defibrase®), and Haemocoagulase (Reptilase®). No specific clinical trial results are published since the company primarily supplies ingredients rather than developing finished therapeutics.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pentapharm AG.